[Prolonged molecular response induced by imatinib in Philadelphia positive acute lymphoblastic leukemia A case report and brief review]. / Rémission moléculaire prolongée induite par l'imatinib dans la leucémie aiguë lymphoblastique avec chromosome de Philadelphie Cas clinique et revue de la littérature.
Ann Biol Clin (Paris)
; 73(2): 195-8, 2015.
Article
em Fr
| MEDLINE
| ID: mdl-25847743
ABSTRACT
Philadelphia or BCR-ABL positive acute lymphoblastic leukemia (PH+ ALL) is the most common and severe of adult ALL. The only potentially curator treatment remains allogeneic hematopoietic stem cells transplantation (SCT) in first complete remission. The use of imatinib has revolutionized the treatment of chronic myeloid leukemia. Its incorporation into PH + ALL protocols also improved the prognosis of this disease giving better complete remission rates compared to chemotherapy alone. The treatment of patients not eligible for SCT remains controversial. Prolonged use of high dose tyrosine kinase inhibitors (TKI) (ie imatinib at 600 or 800 mg/j) as maintenance therapy seems to be a reasonable approach. We present a case of prolonged molecular remission of PH+ ALL under TKI alone as maintenance therapy.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Cromossomo Filadélfia
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Mesilato de Imatinib
Tipo de estudo:
Guideline
/
Prognostic_studies
Limite:
Adult
/
Humans
Idioma:
Fr
Revista:
Ann Biol Clin (Paris)
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Marrocos